Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
| ▸ | DUT | P33316 | 3/20 | 0.34 |
| ▸ | TOP2A | P11388 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30106079 | 0.90 | FKBP1A (0.37) | FKBP1ADUTTOP2A | |
| SCHEMBL420855 | 0.90 | FKBP1A (0.37) | FKBP1ADUTTOP2A | |
| SCHEMBL9606663 | 0.90 | FKBP1A (0.37) | FKBP1ADUTTOP2A | |
| SCHEMBL3400579 | 0.84 | FKBP1A (0.33) | FKBP1ADUTTOP2A | |
| SCHEMBL7790340 | 0.84 | DUT (0.35) | DUT | |
| SCHEMBL15570491 | 0.84 | FKBP1A (0.32) | FKBP1A | |
| SCHEMBL8062803 | 0.82 | FKBP1A (0.33) | FKBP1ADUTTOP2A | |
| SCHEMBL12632024 | 0.82 | FKBP1A (0.33) | FKBP1ADUTTOP2A | |
| SCHEMBL31335101 | 0.82 | FKBP1A (0.34) | FKBP1A | |
| SCHEMBL11970804 | 0.81 | TOP2A (0.38) | FKBP1ADUTTOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727940-A1 | DIHYDROPYRIMIDINE-2, 4 (1H, 3H) -DIONE-CONTAINING POLYCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREOF AND USE THEREOF | Linkcure Therapeutics (KY) | 2026-04-22 | — | — | EP | disclosed |
| WO-2025137605-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR | C4 THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-20250084041-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | THE UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2025-03-13 | — | — | US | disclosed |
| WO-2024255810-A1 | DIHYDROPYRIMIDINE-2, 4 (1H, 3H) -DIONE-CONTAINING POLYCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREOF AND USE THEREOF | HANGZHOU GLUBIO PHARMACEUTICAL CO., LTD (CN) | 2024-12-19 | — | — | WO | disclosed |
| US-12150995-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| EP-4457217-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | Curza Global LLC (US) | 2024-11-06 | — | — | EP | disclosed |
| WO-2024173646-A1 | CYCLIN-DEPENDENT KINASE DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| EP-4271664-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| WO-2023193789-A1 | WEE1 DEGRADING COMPOUNDS | BEIJING NEOX BIOTECH LIMITED (CN) | 2023-10-12 | — | — | WO | disclosed |
| WO-2010088167-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-08-05 | — | — | WO | disclosed |
| US-20090137597-A1 | Novel quinoxalinone derivatives | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7396953-B2 | Angiogenesis inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-07-08 | — | — | US | disclosed |
| US-7396953-B2 | Angiogenesis inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-07-08 | — | — | US | disclosed |
| US-7388010-B2 | Quinoxalinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-17 | — | — | US | disclosed |
| US-20070167519-A1 | Novel Angiogenesis inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-07-19 | — | — | US | disclosed |
| US-20070167519-A1 | Novel Angiogenesis inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-07-19 | — | — | US | disclosed |
| US-20070167519-A1 | Novel Angiogenesis inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-07-19 | — | — | US | disclosed |
| EP-1763500-A1 | NOVEL ANGIOGENESIS INHIBITORS AND PHARMACEUTICAL AND COSMETIC USE THEREOF | Galderma Research & Development, S.N.C. (FR) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006010859-A1 | NOVEL ANGIOGENESIS INHIBITORS AND PHARMACEUTICAL AND COSMETIC USE THEREOF | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | FKBP1A 2212/4885DUT 1964/4885TOP2A 3390/4885 |
| US-20070167519-A1 | Novel Angiogenesis inhibitors and pharmaceutical/cosmetic applications thereof | FLT1, VEGFA, FGF1 | FKBP1A 1180/4885DUT 1967/4885TOP2A 3125/4885 |
| US-20090137597-A1 | Novel quinoxalinone derivatives | NDUFB1, NDUFB6, NDUFB7 | FKBP1A 4460/4885DUT 3283/4885TOP2A 768/4885 |
| US-12150995-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | FKBP1A 2212/4885DUT 1964/4885TOP2A 3390/4885 |
| US-20250084041-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | MPO, NISCH, RPN2 | FKBP1A 3031/4885DUT 83/4885TOP2A 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.